Skip Navigation LinksHome > August 2014 - Volume 33 - Issue 8 > Ceftaroline Activity Tested Against Bacterial Isolates From...
Pediatric Infectious Disease Journal:
doi: 10.1097/INF.0000000000000307
Antimicrobial Reviews

Ceftaroline Activity Tested Against Bacterial Isolates From Pediatric Patients: Results from the Assessing Worldwide Antimicrobial Resistance and Evaluation Program for the United States (2011–2012)

Sader, Helio S. MD, PhD; Mendes, Rodrigo E. PhD; Farrell, David J. PhD; Flamm, Robert K. PhD; Jones, Ronald N. MD

Supplemental Author Material
Collapse Box

Abstract

Background:

Ceftaroline, the active form of ceftaroline fosamil, is a cephalosporin with broad-spectrum bactericidal activity against resistant Gram-positive organisms, including methicillin-resistant Staphylococcus aureus, ceftriaxone-resistant Streptococcus pneumoniae and many Enterobacteriaceae species. Ceftaroline fosamil is approved in the United States for treatment of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia in adults.

Methods:

A total of 5291 consecutive unique pediatric patient strains of clinical significance were collected from 157 US medical centers. The isolates were identified locally and forwarded to a central monitoring laboratory for reference antimicrobial susceptibility testing. S. pneumoniae isolates from the 2011 to 2012 respiratory season were serotyped. Susceptibility results were analyzed according to patient age as follows: ≤1 years old (yo; 1857 strains); 2–5 (1342); 6–12 (1281) and 13–17 (811).

Results:

Methicillin-resistant Staphylococcus aureus rates were slightly lower in isolates from patients 13–17 yo (39.9%) compared with other age groups (48.2–51.5%), and ceftaroline was consistently active against S. aureus isolates from all 4 age groups [minimal inhibitory concentration (MIC50/90): 0.25–05/1 μg/mL; 99.8–100.0% susceptible]. Overall, 99.8% of methicillin-resistant Staphylococcus aureus were ceftaroline susceptible (MIC50/90: 0.5/1 μg/mL). All S. pneumoniae strains (1178) were ceftaroline susceptible (MIC50/90: ≤0.015/0.12 μg/mL), whereas ceftriaxone susceptibility varied from only 84.8 (≤1 yo) to 89.7% (13–17 yo). 19A was the most frequent serotype identified among S. pneumoniae and these isolates exhibited low susceptibility to ceftriaxone (42.4%) and most other antimicrobials tested. The highest ceftaroline MIC among Haemophilus influenzae (587 strains) was 0.12 μg/mL (100.0% susceptible), and β-lactamase production rates varied from 24.2 (13–17 yo) to 30.1% (6–12 yo); 27.9% overall. Ceftaroline was also active against β-hemolytic streptococci (556 strains, highest MIC, 0.06 μg/mL). Extended-spectrum β-lactamase (ESBL)-phenotype rates among Escherichia coli/Klebsiella spp. were 6.0/5.1, 11.0/11.5, 5.1/8.3 and 11.4/14.7% for the ≤1, 2–5, 6–12 and 13–17 yo age groups, respectively. Ceftaroline exhibited good activity against non-ESBL phenotype strains of E. coli and Klebsiella spp. (MIC90: 0.25 μg/mL for both organisms), but had limited activity against ESBL-producing strains.

Conclusion:

Ceftaroline demonstrated potent in vitro activity when tested against S. aureus, S. pneumoniae, H. influenzae, β-hemolytic streptococci and non-ESBL-phenotype E. coli and Klebsiella spp. strains isolated from pediatric patients, independent of patient age.

Copyright © 2014 by Lippincott Williams & Wilkins

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.